by James Lyons-Weiler, PhD, Popular Rationalism, ©2026
(Feb. 23, 2026) — The U.S. intelligence community has just assisted the Mexican government in a military operation against a Mexican drug cartel. It’s about time they join in the fight against illegal drug prescription and over-prescription of pain medications.
Many people assume that only opioid pain medicines can cause dependence. In reality, several non-opioid medications commonly used in pain care can also lead to physical dependence, withdrawal symptoms, or addiction-like patterns. These effects happen through different biological pathways but can lead to the same outcome: the body adapts to the medication, symptoms return when it is stopped, and patients may feel unable to discontinue it—even when harms begin to outweigh benefits.
Drugs such as benzodiazepines and prescription sleep medications can cause tolerance and withdrawal, including serious complications like seizures in severe cases. Gabapentin and pregabalin, widely used for nerve pain, have emerging evidence of misuse and can increase breathing risks when combined with other sedating drugs. Some antidepressants prescribed for pain can produce difficult discontinuation symptoms that are often mistaken for relapse of the original condition. Dopamine-acting medications can trigger impulse-control behaviors such as compulsive gambling or shopping. Long-term corticosteroid use can suppress the body’s natural hormone system, creating a form of physiologic dependence that requires careful tapering.
Other pain-adjacent medications—including certain muscle relaxants, barbiturate-containing headache products, ketamine, and even some over-the-counter sedatives—also carry dependence or misuse potential. However, national surveillance systems primarily measure “misuse” (use not directed by a doctor) and do not track physiologic dependence that develops during compliant medical treatment. As a result, the true population burden of non-opioid iatrogenic dependence remains incompletely quantified.
This report synthesizes regulatory warnings, national survey data, systematic reviews, and pharmacovigilance findings to clarify the mechanisms, risks, and clinical management considerations for non-opioid iatrogenic dependence in pain care. The evidence supports a shift from viewing dependence as a moral failing to recognizing it as a predictable pharmacologic effect under certain exposure conditions—one that requires informed prescribing, patient counseling, careful monitoring, and structured tapering when discontinuation is indicated. Future reports will focus on integrative approaches to mental health that provide alternatives to heavy pharmacologic means of pain management and a policy priority report tailored to effect action on HHS agency and the practice of pain management medicine.
Read the rest here.